Adma Biologics reported $75.63M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Adma Biologics USD 75.63M 8.4M Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Takeda JPY 790.55B 262.97B Dec/2025